Feds Take Hard Look at Medtronic Bone-Growth Products

Share This:

Medtronic’s bone-growth products are coming under increasing scrutiny by the federal government.

The New York Times reports that the Food and Drug Administration (FDA) recently rejected the company’s request to sell a new spinal infusion device called Amplify, a stronger version of its already approved Infuse Bone Growth product. Now, it appears that a Department of Justice investigation into the marketing of Infuse is broadening. However, the company has not been charged to date with any wrongdoing in the long-running investigation.

The FDA issued a warning in 2008 regarding the use of bone-growth proteins in an off-label fusion procedure used to treat neck pain, citing reports of life-threatening injuries.

If you or a loved one has suffered an injury due to a medical device, you may want to contact an attorney to learn about your legal rights and see what types of legal action you may be able to pursue.

Learn more